Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key in sepsis modulation?

38. Canaud B, Mingardi G, Braun J et al. STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23: 3654–3661 39. Levin NW, Fishbane S, Cañedo FV et al. MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415–1421 40. Sulowicz W, Locatelli F, Ryckelynck JP et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637– 646 41. Spinowitz B, Coyne DW, Lok CE et al. RUBRA Study Investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2008; 28: 280–289 42. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469–475 43. Hermeling S, Schellekens H, Crommelin DJ et al. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 2003; 20: 1903–1907 44. Bennett CL, Cournoyer D, Carson KR et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106: 3343–3347 45. Eckardt KU, Macdougall IC, Froissart M et al. Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with HematideTM. Nephrol Dial Transplant 2008; 1(Suppl 2): i216 (abstract) 46. Woodburn KW, Fan Q, Winslow S et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35: 1201–1208 47. FDA Briefing Document. Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy: Hearings before the Subcommittee on Oncologic Drugs Advisory Committee, Center for Drug Evaluation and Research. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B2_ 04_ FDA-Aranesp-Procrit.htm#_ednref45 48. FDA Briefing Document. 10 May 2007: Oncologic Drugs Advisory Committee. Continuing reassessment of the risks of erythropoiesisstimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf